title: [Cardioverter-defibrillator in the treatment of arrhythmia induced by trastuzumab used in the adjuvant setting in a patient with positive human epidermal growth factor receptor type-2 breast cancer].
abstract: A case of a 36-year old woman with HER2-positive early breast cancer treated with adjuvant trastuzumab left ventricle dysfunction and cardiac arrest in ventricular fibrillation mechanism is presented. After having been successfully resuscitated, trastuzumab therapy was withheld, pharmacotherapy (beta-blocker, ACE-I) implemented and ICD was implanted. Echocardiography performed 6 months later, revealed normal systolic function of the left ventricle. The patient died despite further oncologic treatment due to progression of the disease. The authors discuss the approach to this dramatic but lone cardiac side effect of trastuzumab treatment.
authors: Oddział Kardiologii, Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Łódź. gpiotr4@wp.pl
authors: Grzegorz
authors: G
authors: Piotrowski
authors: Rafał
authors: R
authors: Gawor
authors: Robert
authors: R
authors: Słomka
authors: Maciej
authors: M
authors: Banasiak
authors: Paweł
authors: P
authors: Strzelecki
authors: Zenon
authors: Z
authors: Gawor
authors: Piotr
authors: P
authors: Potemski
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000628:therapy*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D017147:Defibrillators, Implantable; D004452:Echocardiography; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab